Cannatrek Japan

Cannatrek leads signing of first MoU between Australia and Japan for the advancement of medicinal cannabis research

  • Cannatrek leads advancement in medical cannabis research with its signing of a MoU with Mie University in Tsu, Japan
  • The MoU focuses on a collaborative effort from both parties to further agronomic and medical research for medical cannabis

Melbourne, Australia – 30 January 2024 Cannatrek, Australia’s leading vertically integrated plant-based medicine company, has signed a Memorandum of Understanding (MoU) with Mie University in Tsu, Japan, to forge an open collaboration focused on accelerating medical research into the use of cannabis. The strategic partnership marks the first-ever MoU for medicinal cannabis research between any Australian and Japanese organisation or government.

The MoU swiftly follows the Japanese Government’s recent change in stance towards the use of cannabis with the Lower House passing the bill to legalise the use of medical products made from cannabis in mid-November.

“We are honoured to be the first Australian business to have a MoU for medicinal cannabis research with a Japanese organisation” says Cannatrek CEO Tommy Huppert.

“Cannatrek has the manufacturing capability to supply the highest quality of medicinal cannabis products for domestic and international markets via our Shepparton facility. The facility recently received Good Manufacturing Practice (GMP) accreditation which further enhances export opportunities”.

Under the MoU, the framework for cooperation encompasses several key areas including agronomic research, training resources for clinicians, pharmaceutical supply chain, e-healthcare, navigating regulation and compliance and connecting experts in the field.

Cannatrek CEO – Tommy Huppert and MIE University Director – Imanishi Nobuyuki.

For further information, please contact Emilie O’Malley (

About Cannatrek
Cannatrek is a vertically integrated, Australian-owned producer and health tech company that offers plant- based medicines and digital health services. Cannatrek is redefining the Australian healthcare industry through its end-to-end supply chain, from seed to patient.

Information about studies provided by Cannatrek on this website is for education purposes only. It is not a substitute for professional health advice. Nothing contained in this site, or any external site linked to by Cannatrek, is intended to be used as medical advice and it is not intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used for therapeutic purposes or as a substitute for your own health professional’s advice. Cannatrek does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information provided on this website, or any external site linked to by Cannatrek. Further, Cannatrek accepts no responsibility for material contained in a website that is linked to this site. It is the responsibility of the user to make their own decisions about the accuracy, currency, reliability and correctness of information contained in linked external websites.